Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
作者信息
Murphy Conor F, le Roux Carel W
机构信息
Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.
Gastrosurgical laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
出版信息
Ann Transl Med. 2018 May;6(10):186. doi: 10.21037/atm.2018.03.06.
Abstract
摘要
相似文献
1
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?我们能否免除胰高血糖素样肽-1（GLP-1）受体激动剂引发胰腺不良事件的责任？
Ann Transl Med. 2018 May;6(10):186. doi: 10.21037/atm.2018.03.06.
2
Adverse Effects of GLP-1 Receptor Agonists.胰高血糖素样肽-1受体激动剂的不良反应
Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10.
3
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者的心血管结局：一项荟萃分析。
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.
4
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.GLP-1 受体激动剂治疗 2 型糖尿病的安全性和耐受性：综述。
Diabetes Metab Res Rev. 2011 Sep;27(6):528-42. doi: 10.1002/dmrr.1202.
5
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
6
The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂对心血管的影响：一项随机对照试验的试验序贯分析。
J Clin Pharm Ther. 2014 Feb;39(1):7-13. doi: 10.1111/jcpt.12102. Epub 2013 Oct 16.
7
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.存在心血管风险的2型糖尿病患者使用基于肠促胰岛素的药物：比较胰高血糖素样肽-1激动剂和二肽基肽酶-4抑制剂对心血管和胰腺结局的影响。
Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z.
8
Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?胰高血糖素样肽-1 受体 (GLP-1R) 激动剂是否有潜力作为 1 型糖尿病的辅助治疗药物？
Expert Opin Pharmacother. 2018 Oct;19(15):1655-1661. doi: 10.1080/14656566.2018.1519547. Epub 2018 Sep 20.
9
An updated review on cancer risk associated with incretin mimetics and enhancers.关于肠促胰岛素类似物和增强剂相关癌症风险的最新综述。
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(1):67-124. doi: 10.1080/10590501.2015.1003496.
10
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.2型糖尿病中胰高血糖素样肽-1受体激动剂：随机临床试验的荟萃分析。
Eur J Endocrinol. 2009 Jun;160(6):909-17. doi: 10.1530/EJE-09-0101. Epub 2009 Mar 24.
引用本文的文献
1
Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.胰高血糖素样肽-1受体激动剂的使用与结直肠癌风险之间的关联：一项系统评价和荟萃分析。
Health Sci Rep. 2025 Feb 19;8(2):e70490. doi: 10.1002/hsr2.70490. eCollection 2025 Feb.
2
Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.度拉糖肽单药治疗与格列美脲相比在初治2型糖尿病中国患者中的疗效和安全性：AWARD-CHN1的事后分析
Diabetes Ther. 2020 May;11(5):1077-1090. doi: 10.1007/s13300-020-00799-w. Epub 2020 Mar 26.
本文引用的文献
1
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.利拉鲁肽治疗 2 型糖尿病患者的淀粉酶、脂肪酶和急性胰腺炎：来自 LEADER 随机试验的结果。
Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5.
2
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.胰高血糖素样肽-1 受体激动剂（胰腺炎、胰腺癌和胆石症）的安全性问题：来自随机对照试验的数据。
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20.
3
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.利拉鲁肽治疗 3 年对糖尿病前期个体的 2 型糖尿病风险降低和体重管理的效果：一项随机、双盲试验。
Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23.
4
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者急性胰腺炎风险的关系。
Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17.
5
Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.基于肠促胰岛素的疗法与2型糖尿病患者患胰腺癌的风险：一项随机对照试验的荟萃分析
Diabetes Ther. 2016 Dec;7(4):725-742. doi: 10.1007/s13300-016-0198-3. Epub 2016 Sep 21.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.基于肠促胰岛素的药物与胰腺癌风险：国际多中心队列研究
BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581.
8
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.利拉鲁肽 3.0 毫克在体重管理中的随机、对照试验。
N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
9
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者体重减轻的影响：一项系统评价与混合治疗比较的Meta分析
PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.
10
Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.基于肠降血糖素的药物与胰腺不良事件：近十年后，不确定性依然存在。
Diabetes Care. 2015 Jun;38(6):951-3. doi: 10.2337/dc15-0347.
Zotero 插件